LU82700A1 - Nouvelle utilisation en therapie du produit(2-benzofuryl)-(p-chlorophenyl)-carbinol(cloridarol,dci)en tant que normolipidemiant et antiagregant plaquettaire - Google Patents
Nouvelle utilisation en therapie du produit(2-benzofuryl)-(p-chlorophenyl)-carbinol(cloridarol,dci)en tant que normolipidemiant et antiagregant plaquettaire Download PDFInfo
- Publication number
- LU82700A1 LU82700A1 LU82700A LU82700A LU82700A1 LU 82700 A1 LU82700 A1 LU 82700A1 LU 82700 A LU82700 A LU 82700A LU 82700 A LU82700 A LU 82700A LU 82700 A1 LU82700 A1 LU 82700A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- cloridarol
- benzofuryl
- carbinol
- dci
- product
- Prior art date
Links
- KBFBRIPYVVGWRS-UHFFFAOYSA-N cloridarol Chemical compound C=1C2=CC=CC=C2OC=1C(O)C1=CC=C(Cl)C=C1 KBFBRIPYVVGWRS-UHFFFAOYSA-N 0.000 title claims description 13
- 229960001261 cloridarol Drugs 0.000 title claims description 12
- 238000002560 therapeutic procedure Methods 0.000 title claims description 7
- -1 2-BENZOFURYL Chemical class 0.000 title claims description 4
- 230000002744 anti-aggregatory effect Effects 0.000 title 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000000444 normolipidemic effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000000702 anti-platelet effect Effects 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT951379 | 1979-08-10 | ||
| IT7909513A IT1207887B (it) | 1979-08-10 | 1979-08-10 | Uso in terapia del prodotto (2benzofuril)-(p-clorofenil)-carbino lo(cloridarol dci)come normolipide mizzante e antiaggregante piastrinico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU82700A1 true LU82700A1 (fr) | 1980-12-15 |
Family
ID=11131363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU82700A LU82700A1 (fr) | 1979-08-10 | 1980-08-08 | Nouvelle utilisation en therapie du produit(2-benzofuryl)-(p-chlorophenyl)-carbinol(cloridarol,dci)en tant que normolipidemiant et antiagregant plaquettaire |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4296124A (ref) |
| JP (1) | JPS5645413A (ref) |
| BE (1) | BE884691A (ref) |
| CA (1) | CA1155395A (ref) |
| CH (1) | CH648756A5 (ref) |
| DE (1) | DE3029421A1 (ref) |
| FR (1) | FR2463135A1 (ref) |
| GB (1) | GB2056280A (ref) |
| IT (1) | IT1207887B (ref) |
| LU (1) | LU82700A1 (ref) |
| NL (1) | NL8004534A (ref) |
| ZA (1) | ZA804822B (ref) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1160925A (en) | 1967-02-08 | 1969-08-06 | Menarini Sas | 2-Substituted Benzofuran Derivatives |
-
1979
- 1979-08-10 IT IT7909513A patent/IT1207887B/it active
-
1980
- 1980-08-01 GB GB8025197A patent/GB2056280A/en not_active Withdrawn
- 1980-08-02 DE DE19803029421 patent/DE3029421A1/de active Granted
- 1980-08-07 ZA ZA00804822A patent/ZA804822B/xx unknown
- 1980-08-08 CH CH6040/80A patent/CH648756A5/it not_active IP Right Cessation
- 1980-08-08 BE BE0/201683A patent/BE884691A/fr not_active IP Right Cessation
- 1980-08-08 LU LU82700A patent/LU82700A1/fr unknown
- 1980-08-08 NL NL8004534A patent/NL8004534A/nl not_active Application Discontinuation
- 1980-08-08 JP JP10839080A patent/JPS5645413A/ja active Granted
- 1980-08-11 US US06/176,867 patent/US4296124A/en not_active Expired - Lifetime
- 1980-08-11 CA CA000357982A patent/CA1155395A/en not_active Expired
- 1980-08-11 FR FR8017691A patent/FR2463135A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2463135B1 (ref) | 1983-08-12 |
| CA1155395A (en) | 1983-10-18 |
| IT1207887B (it) | 1989-06-01 |
| NL8004534A (nl) | 1981-02-12 |
| FR2463135A1 (fr) | 1981-02-20 |
| GB2056280A (en) | 1981-03-18 |
| BE884691A (fr) | 1980-12-01 |
| DE3029421C2 (ref) | 1990-02-22 |
| DE3029421A1 (de) | 1981-02-26 |
| JPS5645413A (en) | 1981-04-25 |
| ZA804822B (en) | 1981-08-26 |
| US4296124A (en) | 1981-10-20 |
| JPH0153244B2 (ref) | 1989-11-13 |
| CH648756A5 (it) | 1985-04-15 |
| IT7909513A0 (it) | 1979-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dowling et al. | Race-dependent health risks of upper body obesity | |
| Luo et al. | Novel terpenoid-type quinones isolated from Pycnanthus angolensis of potential utility in the treatment of type 2 diabetes | |
| FR2774591A1 (fr) | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie | |
| DE69535081T2 (de) | Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis | |
| BE898559A (fr) | Médicament pour le traitement des affections ulcéreuses. | |
| Stout | Insulin stimulation of cholesterol synthesis by arterial tissue | |
| LU82700A1 (fr) | Nouvelle utilisation en therapie du produit(2-benzofuryl)-(p-chlorophenyl)-carbinol(cloridarol,dci)en tant que normolipidemiant et antiagregant plaquettaire | |
| US3560612A (en) | Method of alleviating hypercitricemia | |
| US4749719A (en) | Method of treating skin pigmentation abnormalities with pantetheine-S-sulfonic acid | |
| Willinger et al. | The effect of sodium fluoride at prophylactic and toxic doses on renal structure and function in the isolated perfused rat kidney | |
| FR2619712A1 (fr) | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie | |
| Meyer et al. | Renal function in the elderly | |
| De Coster et al. | A late autosomal dominant form of limb-girdle muscular dystrophy: a clinical, genetic, and morphological study | |
| Sorsby et al. | Protective Effect of Cysteine against Retinal Degeneration induced by lodate and by lodoacetate | |
| DE60209824T2 (de) | Dosierschema für ppar-gamma-aktivatoren | |
| Thomas et al. | Insulin degradation XXV. Glutathione-insulin transhydrogenase activity of rat liver and kidney during the development of stretptozotocin-diabetes | |
| RU2687977C1 (ru) | Способ местного лечения и профилактики гингивита у женщин с беременностью, осложненной гестозом, с применением жевательного фитосубстрата | |
| EP1128829A1 (fr) | Association de riluzole et d'alpha-tocopherol | |
| Follis Jr | Iodine-induced submandibular sialadenitis in the hamster | |
| JONSSON et al. | Colchicine-induced myoneuropathy in a renal transplant patient | |
| JP3007683B2 (ja) | 新規な医薬用途 | |
| Pesigan et al. | Pararosaniline pamoate (CI-403-A) in the treatment of Schistosoma japonicum infection in the Philippines | |
| Hawk et al. | Deficiency of hepatic coproporphyrinogen oxidase in hereditary coproporphyria | |
| Munro et al. | Acute ethylene glycol poisoning: report of a fatal case | |
| Artemchuk et al. | Morphological changes in periodontal tissues of rats in the experimental model of type 2 diabetes mellitus |